Search details
1.
Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer.
Future Oncol
; 20(7): 373-380, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38445372
2.
Quality of life impact in patients with cutaneous toxicities caused by EGFR inhibitors and immunotherapy.
Dermatology
; 2024 Apr 17.
Article
in English
| MEDLINE | ID: mdl-38631324
3.
Multimodal therapy for synchronous bone oligometastatic NSCLC: The role of surgery.
J Surg Oncol
; 125(4): 782-789, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34918785
4.
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Cancer Immunol Immunother
; 70(6): 1583-1592, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33231726
5.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32474768
6.
DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.
Future Oncol
; 15(20): 2349-2360, 2019 Jul.
Article
in English
| MEDLINE | ID: mdl-28440086
7.
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"
Curr Treat Options Oncol
; 20(3): 23, 2019 02 21.
Article
in English
| MEDLINE | ID: mdl-30790063
8.
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.
Future Oncol
; 15(33): 3775-3782, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31709807
9.
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Mediators Inflamm
; 2019: 7652014, 2019.
Article
in English
| MEDLINE | ID: mdl-31827379
10.
Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?
Future Oncol
; 14(10): 919-926, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29528255
11.
From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
Curr Treat Options Oncol
; 17(12): 59, 2016 12.
Article
in English
| MEDLINE | ID: mdl-27766545
12.
Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.
Future Oncol
; 12(10): 1299-307, 2016 May.
Article
in English
| MEDLINE | ID: mdl-26996100
13.
Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors.
Dermatol Res Pract
; 2024: 8859032, 2024.
Article
in English
| MEDLINE | ID: mdl-38249546
14.
The Role of Human Papilloma Virus (HPV) in Primary Lung Cancer Development: State of the Art and Future Perspectives.
Life (Basel)
; 14(1)2024 Jan 10.
Article
in English
| MEDLINE | ID: mdl-38255725
15.
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC.
Curr Probl Cancer
; 46(1): 100787, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34489119
16.
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.
Front Oncol
; 12: 1026020, 2022.
Article
in English
| MEDLINE | ID: mdl-36387232
17.
Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics.
Life (Basel)
; 12(11)2022 Nov 01.
Article
in English
| MEDLINE | ID: mdl-36362907
18.
Anastrozole-related acute hepatitis with autoimmune features: a case report.
BMC Gastroenterol
; 11: 32, 2011 Mar 31.
Article
in English
| MEDLINE | ID: mdl-21453541
19.
Erratum to: From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
Curr Treat Options Oncol
; 17(12): 65, 2016 12.
Article
in English
| MEDLINE | ID: mdl-27995578
20.
Collagenous colitis and atezolizumab therapy: an atypical case.
Clin J Gastroenterol
; 14(1): 165-169, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33151423